Stakeholder perspectives on a risk-benefit framework for genetic testing.
A key to accelerating the appropriate integration of genomic applications into healthcare in the coming decades will be the ability to assess the tradeoffs between clinical benefits and clinical risks of genetic tests in a timely manner. Several factors limit the ability of stakeholders to achieve this objective, including the lack of direct evidence, the lack of a framework to quantitatively assess risk and benefit, and the lack of a formal analytic approach to assess uncertainty. We propose that a formal, quantitative risk-benefit framework may be particularly useful for assessing genetic tests intended to influence health outcomes, and communicating the potential clinical benefits, harms, and uncertainty to stakeholders. As part of the development process for such a framework, a stakeholder meeting was held in Seattle (Wash., USA) in December of 2008, with the objective of discussing a risk-benefit framework, using warfarin pharmacogenomics as a case study. Participants engaged in focused discussion to elucidate the potential role of genetic test risk-benefit analysis in informing decision-making, categorizing genetic tests and directing research prioritization. This research investigation focuses on qualitative analysis of responses elicited from workshop participants during the proceedings of the workshop session. The major findings of the workshop were: (1) stakeholder support for risk-benefit modeling as a tool to structure discussion of the clinical utility of genetic tests; (2) desire for the modeling process to be iterative, transparent, and parsimonious in its presentation to stakeholders, and (3) some concern with the use of quality-adjusted life-years in the evaluation process. The meeting's findings emphasize the potential utility of risk-benefit analysis in genetic test evaluation, and highlight key areas for future research and stakeholder consensus-building.
Roth
Joshua A
JA
Department of Pharmacy, University of Washington, Seattle, WA 98195, USA.
Garrison
Louis P
LP
Burke
Wylie
W
Ramsey
Scott D
SD
Carlson
Rick
R
Veenstra
David L
DL
D005820:Genetic Testing / Q000379:methods*; D023281:Genomics; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D019057:Quality-Adjusted Life Years; D018570:Risk Assessment; D013678:Technology, Pharmaceutical / Q000379:methods; D035501:Uncertainty; D014859:Warfarin / Q000494:pharmacology
D014859:Warfarin
Nat Rev Genet. 2009 Jul;10(7):489-95
19506575
Thromb Haemost. 2004 Jan;91(1):87-94
14691573
Am J Med. 2005 Mar;118(3):251-8
15745723
Value Health. 2009 Mar;12 Suppl 1:S38-9
19250131
Circulation. 2007 Nov 27;116(22):2563-70
17989110
Health Aff (Millwood). 2007 May-Jun;26(3):684-95
17485745
N Engl J Med. 2005 Jun 2;352(22):2285-93
15930419
Clin Pharmacol Ther. 2008 Feb;83(2):312-21
17653141
Genet Med. 2009 Aug;11(8):575-6
19623080
Am J Manag Care. 2004 May;10(5):301-4
15152698
Clin Pharmacol Ther. 2008 Sep;84(3):303-5
18714318
Genet Med. 2009 Jan;11(1):66-73
19125125
Value Health. 2010 Jan-Feb;13(1):8-13
19883405
Qual Health Res. 2005 Nov;15(9):1277-88
16204405
Value Health. 2009 Mar;12 Suppl 1:S36-7
19250130
Health Aff (Millwood). 2009 Sep-Oct;28(5):1366-71
19738253
Pharmacogenetics. 2004 Aug;14(8):539-47
15284536
J Child Fam Nurs. 1999 Sep-Oct;2(5):388-90
10795196
Pharmacoeconomics. 2010;28(1):61-74
20014877
Value Health. 2009 Mar;12 Suppl 1:S27-30
19250128
Clin Pharmacol Ther. 2008 Sep;84(3):301-3
18714317
Ann Intern Med. 2009 Feb 3;150(3):199-205
19189910
Health Serv Res. 2000 Dec;35(5 Pt 3):128-40
16148957